{"id":"W2623329013","doi":"10.1002/hon.2438_50","title":"PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE <scp>B</scp>‐CELL LYMPHOMA (<scp>RRPMBCL</scp>): UPDATED RESULTS FROM THE <scp>KEYNOTE</scp>‐013 TRIAL","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Pembrolizumab; Regimen; Adverse effect; Population; Cohort; Refractory (planetary science); Surgery; Oncology; Gastroenterology; Toxicity; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001672764,0.0008896743,0.000866638,0.0001996278,0.0002737094,0.0006790416,0.0005103601,0.0008653702,0.005004791],"category_scores_gemma":[0.0008169934,0.0003523194,0.0009099247,0.0002996135,0.0003996681,0.0007494004,0.0002732625,0.002175596,0.0009193242],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000711589,"about_ca_system_score_gemma":0.000883372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008528855,"about_ca_topic_score_gemma":0.002226391,"domain_scores_codex":[0.9997136,0.0001465523,0.0000135248,0.00004564198,0.000034706,0.0000460593],"domain_scores_gemma":[0.9996049,0.000074796,0.000113574,0.00003779251,0.00003045943,0.0001384889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8026888,0.02018926,0.01276689,0.001751916,0.002790783,0.0002893301,0.0003032013,0.002018949,0.03245188,0.0004406634,0.01478805,0.1095203],"study_design_scores_gemma":[0.872005,0.08896033,0.02753482,0.0001052052,0.0009958555,0.0004479034,0.00006157548,0.001105687,0.002298405,0.0003750623,0.006087508,0.00002273743],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9805676,0.005788707,0.0007401397,0.001186368,0.0001712938,0.002572952,0.003989702,0.0001063043,0.004877],"genre_scores_gemma":[0.9834024,0.002750632,0.001577089,0.001462103,0.0001551781,0.002242627,0.005356832,0.00003702156,0.003016115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005004791,"threshold_uncertainty_score":0.01674271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02672170501286256,"score_gpt":0.3030244134812918,"score_spread":0.2763027084684293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}